S Hahner
University of Würzburg
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by S Hahner.
The Journal of Clinical Endocrinology and Metabolism | 2009
E. Born-Frontsberg; Martin Reincke; Lars Christian Rump; S Hahner; Sven Diederich; Reinhard Lorenz; Bruno Allolio; Jochen Seufert; Caroline Schirpenbach; Felix Beuschlein; Martin Bidlingmaier; Stephan Endres; Marcus Quinkler
CONTEXT Primary aldosteronism (PA) is associated with vascular end-organ damage. OBJECTIVE Our objective was to evaluate differences regarding comorbidities between the hypokalemic and normokalemic form of PA. DESIGN AND SETTING This was a retrospective cross-sectional study collected from six German centers (German Conns registry) between 1990 and 2007. PATIENTS Of 640 registered patients with PA, 553 patients were analyzed. MAIN OUTCOME MEASURES Comorbidities depending on hypokalemia or normokalemia were examined. RESULTS Of the 553 patients (61 +/- 13 yr, range 13-96), 56.1% had hypokalemic PA. The systolic (164 +/- 29 vs. 155 +/- 27 mm Hg; P < 0.01) and diastolic (96 +/- 18 vs. 93 +/- 15 mm Hg; P < 0.05) blood pressures were significantly higher in hypokalemic patients than in those with the normokalemic variant. The prevalence of cardiovascular events (angina pectoris, myocardial infarction, chronic cardiac insufficiency, coronary angioplasty) was 16.3%. Atrial fibrillation occurred in 7.1% and other atrial or ventricular arrhythmia in 5.2% of the patients. Angina pectoris and chronic cardiac insufficiency were significantly more prevalent in hypokalemic PA (9.0 vs. 2.1%, P < 0.001; 5.5 vs. 2.1%, P < 0.01). Overall, cerebrovascular comorbidities were not different between hypokalemic and normokalemic patients, however, stroke tended to be more prevalent in normokalemic patients. CONCLUSIONS Our data indicate a high prevalence of comorbidities in patients with PA. The hypokalemic variant is defined by a higher morbidity than the normokalemic variant regarding some cardiovascular but not cerebrovascular events. Thus, PA should be sought not only in hypokalemic but also in normokalemic hypertensives because high-excess morbidity occurs in both subgroups.
The Journal of Clinical Endocrinology and Metabolism | 2009
Martin Reincke; Lars Christian Rump; Marcus Quinkler; S Hahner; Sven Diederich; Reinhard Lorenz; Jochen Seufert; Caroline Schirpenbach; Felix Beuschlein; Martin Bidlingmaier; Christa Meisinger; Rolf Holle; Stephan Endres
CONTEXT Primary aldosteronism (PA) is associated with vascular end organ damage. OBJECTIVE We evaluated the newly established German Conns Registry for evidence of renal impairment and compared the data with those from hypertensive subjects of a population-based survey. DESIGN We conducted a case-control study. PATIENTS AND CONTROLS A total of 408 patients with PA from the Conns registry treated in five German centers were matched for age, sex, and body mass index in a 1:1 ratio with 408 hypertensive control subjects from the population-based F3 survey of the Kooperative Gesundheitsforschung in the region of Augsburg (KORA). MAIN OUTCOME MEASURES We measured serum creatinine and calculated glomerular filtration rate (GFR). RESULTS The percentage of patients with a serum creatinine concentration above the normal range of 1.25 mg/dl was higher in patients with PA than in hypertensive controls (29 vs. 10%; P < 0.001). Regression analysis showed that age, male sex, low potassium, and high aldosterone concentrations were independent predictors of a lower GFR. Adrenalectomy reduced systolic blood pressure from a mean of 160 to 144 mm Hg. In parallel, we observed an increase in serum creatinine and a decrease of GFR from 71 to 64 ml/min (P < 0.001). A similar trend was seen after spironolactone treatment. CONCLUSIONS In a large cohort of patients with PA, markers of disease activity such as plasma aldosterone and serum potassium are independent predictors of a lower GFR. Specific interventions, such as adrenalectomy or spironolactone treatment, are associated with a further decline in GFR.
European Journal of Clinical Investigation | 2000
Martin Fassnacht; S Hahner; Felix Beuschlein; A. Klink; Martin Reincke; Bruno Allolio
Adrenostatic compounds are frequently used in the treatment of patients with Cushings syndrome and act via direct inhibition of steroidogenic enzymes. However, additional mechanisms may be involved in the blockade of adrenal steroid secretion. We therefore investigated the effects of aminoglutethimide (AG), metyrapone (MTP) and etomidate (ETO) in the human NCI‐h295 adrenocortical carcinoma cell line.
The Journal of Clinical Endocrinology and Metabolism | 2016
Katharina Lang; K. Weber; Marcus Quinkler; Anna Dietz; Henri Wallaschofski; Anke Hannemann; N. Friedrichs; Lars Christian Rump; Britta Heinze; C. T. Fuss; Ivo Quack; H. S. Willenberg; Martin Reincke; Bruno Allolio; S Hahner
CONTEXT Primary aldosteronism (PA) is the most common cause of secondary hypertension. Aldosterone excess can cause DNA damage in vitro and in vivo. Single case reports have indicated a coincidence of PA with renal cell carcinoma and other tumors. However, the prevalence of benign and malignant neoplasms in patients with PA has not yet been studied. PATIENTS AND DESIGN In the multicenter MEPHISTO study, the prevalence of benign and malignant tumors was investigated in 335 patients with confirmed PA. Matched hypertensive subjects from the population-based Study of Health in Pomerania cohort served as controls. RESULTS Of the 335 PA patients, 119 (35.5%) had been diagnosed with a tumor at any time, and 30 had two or more neoplasms. Lifetime malignancy occurrence was reported in 9.6% of PA patients compared to 6.0% of hypertensive controls (P = .08). PA patients with a history of malignancy had higher baseline aldosterone levels at diagnosis of PA (P = .009), and a strong association between aldosterone levels and the prevalence of malignancies was observed (P = .03). In total, 157 neoplasms were identified in the PA patients; they were benign in 61% and malignant in 25% of the cases (14% of unknown dignity). Renal cell carcinoma was diagnosed in five patients (13% of all malignancies) and was not reported in controls CONCLUSION Compared to hypertensive controls, the prevalence of malignancies was positively correlated with aldosterone levels, tended to be higher in PA patients, but did not differ significantly.
Experimental and Clinical Endocrinology & Diabetes | 2006
Ac Koschker; Martin Fassnacht; S Hahner; D. Weismann; Bruno Allolio
Endocrinology | 2007
Urs Lichtenauer; Marlena Duchniewicz; Mateusz Kolanczyk; Andreas Hoeflich; S Hahner; Tobias Else; Andrew B. Bicknell; Tomasz Zemojtel; Nancy R. Stallings; Dominik M. Schulte; Mark P. Kamps; Gary D. Hammer; Jürgen S. Scheele; Felix Beuschlein
Journal of Endocrinology | 2006
Anthony P. Coll; Martin Fassnacht; Steffen Klammer; S Hahner; Dominik M. Schulte; Sarah Piper; Y.C. Loraine Tung; Benjamin G. Challis; Yacob Weinstein; Bruno Allolio; Stephen O'Rahilly; Felix Beuschlein
Annals of Surgical Oncology | 2006
Dirk Weismann; Martin Fassnacht; Barbara Schubert; Roland Bonfig; Alexander Tschammler; Stephan Timm; S Hahner; Christian Wunder; Bruno Allolio
Experimental and Clinical Endocrinology & Diabetes | 2006
Martin Fassnacht; S Hahner; B Polat; Ac Koschker; M Flentje; Bruno Allolio
Annals of Surgical Oncology | 2006
Dirk Weismann; Martin Fassnacht; Barbara Schubert; Roland Bonfig; Alexander Tschammler; Stephan Timm; S Hahner; Christian Wunder; Bruno Allolio